Caffeine citrate: When and for how long. A literature review

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 25, Issue SUPPL. 3, 2012, Pages 11-14

  Picone, S ^a   Bedetta, M ^a   Paolillo, P ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Apnea of prematurity; Apnoea of prematurity; Bronchopulmonary dysplasia; Caffeine; Neural development

Indexed keywords

ANTICONVULSIVE AGENT; CAFFEINE CITRATE;

BRAIN BLOOD FLOW; BRAIN ISCHEMIA; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; EXTUBATION; GESTATIONAL AGE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; LUNG DYSPLASIA; MEMBRANE PERMEABILITY; MYELINATION; NECROTIZING ENTEROCOLITIS; NEUROPROTECTION; NEWBORN APNEA; NONHUMAN; OXYGENATION; PATENT DUCTUS ARTERIOSUS; PREMATURITY; PRIORITY JOURNAL; RETROLENTAL FIBROPLASIA; REVIEW; SEIZURE; TREATMENT FAILURE; TREATMENT INDICATION;

APNEA; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CITRATES; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES;

EID: 84867015058     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2012.712305     Document Type: Review

References (26)

1. Erenberg A, Leff RD, Haack DG, Mosdell KW, Hicks GM, Wynne BA. Caffeine citrate for the treatment of apnea of prematurity: a doubleblind, placebo-controlled study. Pharmacotherapy 2000;20:644-652.
2. Hascoet JM, Hamon I, Boutroy MJ. Risks and benefits of therapies for apnoea in premature infants. Drug Saf 2000;23:363-379.
3. Julien CA, Joseph V, Bairam A. Caffeine reduces apnea frequency and enhances ventilatory long-term facilitation in rat pups raised in chronic intermittent hypoxia. Pediatr Res 2010;68:105-111.
4. Kassim Z, Greenough A, Rafferty GF. Effect of caffeine on respiratory muscle strength and lung function in prematurely born, ventilated infants. Eur J Pediatr 2009;168:1491-1495.
5. Natarajan G, Botica ML, Thomas R, Aranda JV. Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise? Pediatrics 2007;119:936-940.
6. Zhao J, Gonzalez F, Mu D. Apnea of prematurity: from cause to treatment. Eur J Pediatr 2011;170:1097-1105.
7. Finer NN, Higgins R, Kattwinkel J, Martin RJ. Summary proceedings from the apnea-of-prematurity group. Pediatrics 2006;117:S47-S51.
8. Baird TM, Martin RJ, Abu-Shaweesh JM. Clinical associations, treatment and outcome of apnea of prematurity. NeoReviews 2002;3:e66-70.
9. Martin RJ, Abu-Shaweesh JM. Control of breathing and neonatal apnea. Biol Neonate 2005;87:288-295.
10. Mathew OP. Apnea of prematurity: pathogenesis and management strategies. J Perinatol 2011;31:302-310.
11. Molloy EJ, Di Fiore JM, Martin RJ. Does gastroesophageal reflux cause apnea in preterm infants? Biol Neonate 2005;87:254-261.
12. Janvier A, Khairy M, Kokkotis A, Cormier C, Messmer D, Barrington KJ. Apnea is associated with neurodevelopmental impairment in very low birth weight infants. J Perinatol 2004;24:763-768.
13. Aranda JV, Gorman W, Bergsteinsson H, Gunn T. Efficacy of caffeine in treatment of apnea in the low-birth-weight infant. J Pediatr 1977;90:467-472.
14. Aranda JV, Beharry K, Valencia GB, Natarajan G, Davis J. Caffeine impact on neonatal morbidities. J Matern Fetal Neonatal Med 2010;23 Suppl 3:20-23.
15. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W; Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity. N Engl J Med 2006;354:2112-2121.
16. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W; Caffeine for Apnea of Prematurity Trial Group. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med 2007;357:1893-1902.
17. Steer P, Flenady V, Shearman A, Charles B, Gray PH, Henderson-Smart D, Bury G, et al.; Caffeine Collaborative Study Group Steering Group. High dose caffeine citrate for extubation of preterm infants: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 2004;89:F499-F503.
18. Henderson-Smart DJ, De Paoli AG. Prophylactic methylxanthine for prevention of apnoea in preterm infants (review). The Cochrane Library, 2011 Issue 1.
19. Henderson-Smart DJ, Davis PG. Prophylactic methylxanthines for extubation in preterm infants (review). The Cochrane Library 2009, Issue 4.
20. Davis PG, Schmidt B, Roberts RS, Doyle LW, Asztalos E, Haslam R, Sinha S, Tin W; Caffeine for Apnea of Prematurity Trial Group. Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. J Pediatr 2010;156:382-387.
21. Schmidt B, Anderson PJ, Doyle LW, Dewey D, Grunau RE, Asztalos EV, Davis PG, et al.; Caffeine for Apnea of Prematurity (CAP) Trial Investigators. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA 2012;307:275-282.
22. Tracy MB, Klimek J, Hinder M, et al. Does caffeine impair cerebral oxygenation and blood flow velocity in preterm infants? ActaPediatrica 2010;99:1319-1323.
23. Hoecker C, Nelle M, Poeschl J, Beedgen B, Linderkamp O. Caffeine impairs cerebral and intestinal blood flow velocity in preterm infants. Pediatrics 2002;109:784-787.
24. Chavez Valdez R, Ahlawat R, Wills-Karp M, Nathan A, Ezell T, Gauda EB. Correlation between serum caffeine levels and changes in cytokine profile in a cohort of preterm infants. J Pediatr 2011;158:57-64, 64.e1.
25. Scott Rivkees A, Wendler CC. Adverse and protective influences of adenosine on the newborn and embryo: implications for preterm white matter injury and embryo protection. Pediatr Res 2011;69:271-278.
26. Back SA, Craig A, Luo NL, Ren J, Akundi RS, Ribeiro I, Rivkees SA. Protective effects of caffeine on chronic hypoxia-induced perinatal white matter injury. Ann Neurol 2006;60:696-705.